معرفی
Michael S Kinch is Professor of Pharmacological Sciences at Stony Brook University and serves as Chief Innovation Officer. He founded and directs the Center for Research Innovation in Biotechnology (CRIB), which analyzes trends in drug discovery, development, and commercialization. Previously, he held leadership positions as Executive Dean for Sciences at Long Island University, Associate Vice Chancellor at Washington University in St. Louis, and founded the Yale Center for Molecular Discovery at Yale University.
Dr. Kinch earned his PhD in Immunology from Duke University and a Bachelor's of Science in Molecular Genetics from The Ohio State University. His educational background has provided the foundation for his interdisciplinary work spanning science, medicine, law, and business of drug development.
His research focuses on innovative approaches to improve biomedical translation and entrepreneurship. The CRIB laboratory curates comprehensive information on FDA-approved medicines, vaccines, and drugs in clinical trials, creating a unique database that reveals how medicines work, the diseases they treat, contributing organizations, pricing, and other critical factors. His work identifies trends in drug development and anticipates future challenges and opportunities across pharmaceutical innovation, regulatory science, drug pricing, and academic contributions to drug discovery.
Dr. Kinch's extensive publication record demonstrates consistent focus on FDA approvals, pharmaceutical innovation trends, and the business of drug development. His recent work examines antibiotic development, monoclonal antibodies, bispecific antibodies, and the economic and regulatory challenges facing the pharmaceutical industry, with publications primarily in Drug Discovery Today and related journals.
Dr. Kinch has published more than 150 scientific papers and holds five dozen US patents. He has authored multiple trade books on trends in medicine development and distribution. His research has been featured in prominent media outlets including The Wall Street Journal, The Washington Post, The New York Times, CNN, BBC, and Bloomberg News.
As an academic leader and innovator, Dr. Kinch has established programs to support biomedical entrepreneurship and technology commercialization. His work with translational fellows and university gap funds demonstrates his commitment to bridging the gap between academic research and healthcare applications. The Center for Research Innovation in Biotechnology (CRIB) serves as his primary research laboratory, providing insights into molecular targets and the mechanistic basis of drugs, vaccines, and emerging therapies.
